January 18, 2022

Eli Lilly to Seek FDA Approval for Alzheimer’s Drug

Eli Lilly & Co. plans to seek approval for its Alzheimer’s drug later this year, a sign that regulators are accelerating the prospects of treatments for the disease after a recent approval.

Lilly said Thursday that the U.S. Food and Drug Administration had designated the company’s experimental Alzheimer’s drug, called donanemab, for expedited review, and it would seek the drug’s approval under the agency’s accelerated-approval pathway.

The FDA decision comes after the agency cleared Biogen Inc.’s Aduhelm, the first Alzheimer’s therapy to receive approval in nearly two decades but one that has drawn criticism from doctors and researchers skeptical the drug works.

Lilly stock climbed more than 6% in morning trading. Many analysts predicted donanemab would be approved, perhaps by the middle of next year, and become a multibillion-dollar seller.

Shares in Biogen, meanwhile, dropped nearly 6% on concerns the company’s newly approved Alzheimer’s drug could face stiff competition sooner than expected.

Donanemab performed better in a trial than Biogen’s drug did in its trials, and health insurers and patients would probably prefer it over Aduhelm, J.P. Morgan analyst Chris Schott said in a note to investors.

“Donanemab’s approval would be a major blow to Aduhelm’s commercial prospects.” Brian Skorney, a Robert W. Baird & Co. analyst, said in a research note. “We think it would make zero sense for FDA to approve Aduhelm, but not donanemab.”

Alzheimer’s is a progressive disease robbing people of their memories and cognitive abilities. About six million people in the U.S. have Alzheimer’s, according to the U.S. Centers for Disease Control and Prevention.

Few drugs have been approved to treat the disease, and most merely treat symptoms, rather than slowing its progression.

For years, drug researchers struggled to find effective treatments, and repeat failures drove many companies to abandon efforts. After it encountered disappointing trial results, Biogen ended its exploration of Aduhelm, before taking a closer look at the data and reviving the program.

The FDA encouraged Biogen’s re-examination, according to documents the agency released earlier this week.

In approving Aduhelm, the FDA said the drug reduced amyloid, a sticky substance in the brain associated with Alzheimer’s, and reducing amyloid should help patients.

Wall Street analysts said the agency’s reasoning bolstered the prospects of donanemab and other experimental drugs targeting amyloid and could open the door to their approval.

Biogen and partner Eisai Co. Ltd. said on Wednesday that the FDA designated their experimental Alzheimer’s drug lecanemab for a speedy review.

The Aduhelm approval, however, has been criticized by many researchers and doctors, who say the amyloid hypothesis is unproven and study data don’t prove the drug works. Some of the critics have said it isn’t worth paying for Aduhelm, which Biogen listed for $56,000 a year.

Statisticians at the FDA also objected to approving Aduhelm, saying there was insufficient evidence, according to the agency’s documents. Since the approval, three members of an FDA panel that advised the agency to reject Aduhelm have resigned in protest.

In January, Lilly said donanemab in a small, mid-stage trial slowed the decline in memory and ability to perform activities of daily living by 32% in subjects who got the therapy after 18 months. The Indianapolis-based company said it will ask for approval based on data from the Phase 2 trial, though it is testing donanemab in a large, late-stage trial.

Write to Laura Cooper at laura.cooper@wsj.com

Copyright ©2020 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Related Posts

Canadian Pacific Declines to Increase Offer for Kansas City Southern

May 20, 2021

May 20, 2021

Canadian Pacific Railway Ltd. said Thursday it won’t increase its takeover offer for Kansas City Southern , betting recent setbacks...

Biden Administration Outlines Measures to Address Supply-Chain Issues

June 8, 2021

June 8, 2021

WASHINGTON—The Biden administration outlined new measures Tuesday to address widespread supply-chain issues, with a goal of bringing manufacturing back to...

Ant Wins China’s Approval to Set Up Consumer-Finance Company

June 3, 2021

June 3, 2021

China’s banking and insurance regulator said Thursday that it had approved an application by Ant Group Co. to set up...

Companies in Certain Industries Receive More Auditor Warnings About Survival

June 21, 2021

June 21, 2021

The number of U.S. public companies labeled with auditor warnings about the ability to stay afloat declined overall during the...

Facebook Advertising Boss Carolyn Everson Leaving the Social-Media Company

June 9, 2021

June 9, 2021

Carolyn Everson, Facebook Inc.’s FB -1.03% head of global advertising sales and one of the ad industry’s most powerful executives,...

It May Soon Be Time to Think About Tapering Bond-Buying

June 2, 2021

June 2, 2021

Federal Reserve Bank of Philadelphia leader Patrick Harker on Tuesday said he is getting ready to think about paring central...

Social Security Weathered Covid-19 Better Than Expected, but Long-Term Challenges Remain

June 11, 2021

June 11, 2021

WASHINGTON—When the coronavirus pandemic plunged the U.S. into a recession last year, it portended another blow to the health of...

‘Friday’ Franchise Frozen as Ice Cube and Warner Bros. Fight Over New Movie

July 1, 2021

July 1, 2021

A spat between star Ice Cube and WarnerMedia has escalated into a high-stakes blame game that threatens to permanently derail...

Do Women Still Want to Go to the Movies?

November 11, 2021

November 11, 2021

The movie industry has a problem that could outlast the coronavirus pandemic. Women over 35 haven’t come back to theaters....

The Economic Recovery Is Here. It’s Unlike Anything You’ve Seen.

June 2, 2021

June 2, 2021

The U.S. economic recovery is unlike any in recent history, powered by consumers with trillions in extra savings, businesses eager...

William Ackman SPAC Nears $40 Billion Universal Music Deal

June 3, 2021

June 3, 2021

Hedge-fund billionaire William Ackman’s special-purpose acquisition company is nearing a transaction with Universal Music Group that would value the world’s...

Samsung Posts Record Quarterly Revenue From Chip Boom

October 28, 2021

October 28, 2021

SEOUL— Samsung Electronics Co. reported record quarterly revenue and saw net profit grow by 31% on the back of booming...

Belarus Forced Landing Prompts Budget Airline to Redirect Flight

May 24, 2021

May 24, 2021

Wizz Air Holdings PLC, a European discount carrier, said it was rerouting a flight from Kyiv to Tallinn, Estonia, to...

Technology Provider Kaseya Warns of Cyberattack

July 3, 2021

July 3, 2021

Kaseya Ltd. warned Friday afternoon that a key software tool used by companies to manage technology at other businesses may...

AMC Boss Adam Aron Basks in Meme-Stock Spotlight

June 4, 2021

June 4, 2021

Adam Aron, AMC Entertainment Holdings Inc.’s AMC -6.68% chief executive, has decided to run with the meme-stock bulls who helped...